Making Early CKD Detection Count: Ralph Riello, PharmD, and Nihar Desai, MD

Why It Matters

Closing the detection‑to‑treatment gap can dramatically reduce CKD progression and associated cardiovascular events, while expanding prescribing authority improves access and equity across the health system.

Key Takeaways

• uACR screening remains underused despite guideline recommendations
• Only 1 nephrologist per 2,000 CKD patients limits referrals
• Primary care, cardiology, endocrinology must initiate guideline‑directed therapy
• SGLT2 inhibitors, finerenone, GLP‑1 agonists improve outcomes across CKD
• Racial, geographic, insurance gaps hinder equitable CKD treatment access

Pulse Analysis

Early identification of chronic kidney disease has long been a cornerstone of preventive health, yet the United States still struggles to translate a positive urine albumin‑to‑creatinine ratio (uACR) into timely therapeutic action. The recent episode of "Beyond the Silo" spotlights this disconnect, arguing that the traditional reliance on nephrology referrals is unsustainable given the roughly one specialist for every 2,000 CKD patients. By empowering primary‑care physicians, cardiologists, and endocrinologists to interpret and act on uACR results, the care model shifts from reactive to proactive, aligning with the broader integrated‑care movement championed by managed‑care organizations.

The therapeutic arsenal for CKD has expanded dramatically in the past five years. Sodium‑glucose cotransporter‑2 (SGLT2) inhibitors now demonstrate mortality and renal‑function benefits across heart failure, atherosclerotic disease, and CKD regardless of diabetes status. Finerenone, a non‑steroidal mineralocorticoid receptor antagonist, adds further cardiovascular and renal protection, especially when combined with SGLT2 inhibitors, while GLP‑1 receptor agonists round out a multi‑modal strategy. Despite compelling trial data, uptake remains limited outside nephrology, underscoring the need for broader prescribing authority and education among non‑specialist clinicians.

Equity concerns loom large as cost, insurance coverage, and systemic bias intersect to leave vulnerable populations behind. Branded therapies, while clinically superior, pose affordability challenges that disproportionately affect patients of color, rural residents, and those with public insurance. Advocacy at both the clinical and policy levels—such as formulary negotiations, value‑based contracts, and targeted outreach—can mitigate these barriers. The podcast’s call to action—"What can I do tomorrow that I didn’t do today?"—encourages clinicians to adopt routine uACR testing, familiarize themselves with CKD staging, and initiate guideline‑directed therapies now, accelerating the shift toward a more equitable, outcomes‑driven kidney care paradigm.